Bioxydyn, Ltd. and Queen Square Analytics Ltd. today announced a strategic partnership to provide advanced clinical trial services in the neurological treatment arena.
As partners, Bioxydyn and QSA will jointly provide a comprehensive set of clinical trial services for multiple sclerosis (MS) and other neurological disorders. The offering includes:
Consultancy and tailored advice on MR biomarkers and imaging study design, ensuring a robust foundation for each trial.
Imaging protocol development, including development of Imaging Manuals and Imaging Charters.
Worldwide site training and qualification, available both in-person and remotely.
Efficient, secure, and compliant imaging handling and data transfer.
Rigorous image QC alongside mature query and feedback processes, with images checked as they arrive, and feedback provided to sites so that high quality acquisition and calibration is maintained.
State-of-the-art image analysis employing both traditional techniques and advanced analytics for stratification and data-driven subtyping in multiple sclerosis and neurological disorders.
Comprehensive reporting with the option for expert scientific interpretation tailored to customer requirements.
Secure data archive, providing long-term data preservation and access.
Matthew Heaton, Director of Operations for Bioxydyn, said: “We are excited to support trials in the MS space working in partnership with QSA. Their innovative technologies, established scientific credibility and specialized knowledge in neurological disorders offer powerful insights for our clients.”
Bruce Lynn, CEO of Queen Square Analytics Ltd., said: “Bioxydyn provides years of experience and operational capability to QSA’s latest innovations in applying machine learning and other advanced imaging technologies to clinical trials.”
Bioxydyn provides high-standard, quantitative MRI imaging services to both the pharmaceutical industry and clinical/academic R&D. With over a decade of experience delivering complex, multi-centre clinical trials, Bioxydyn employs robust GxP and 21 CFR Part 11 compliant processes, supported by their cloud-based VoxelFlow data management & analysis platform. Bioxydyn empowers its clients with unique insights into disease progression and drug effects, helps pharmaceutical companies make investment decisions and assists clinicians in developing the best treatment for patients.